Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Chemotherapy Induced Anemia Therapeutics Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Review, H2 2016" drug pipelines to their offering.

Chemotherapy Induced Anemia Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Chemotherapy Induced Anemia pipeline therapeutics constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2, 3 and 7 respectively.

Our latest report Chemotherapy Induced Anemia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Chemotherapy Induced Anemia Overview
  3. Therapeutics Development
  4. Pipeline Products for Chemotherapy Induced Anemia - Overview
  5. Pipeline Products for Chemotherapy Induced Anemia - Comparative Analysis
  6. Chemotherapy Induced Anemia - Therapeutics under Development by Companies
  7. Chemotherapy Induced Anemia - Therapeutics under Investigation by Universities/Institutes
  8. Chemotherapy Induced Anemia Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Chemotherapy Induced Anemia - Products under Development by Companies
  13. Chemotherapy Induced Anemia - Products under Investigation by Universities/Institutes
  14. Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
  • 3SBio Inc.
  • BIOCAD
  • Chong Kun Dang Pharmaceutical Corp.
  • Dr. Reddy's Laboratories Limited
  • Galenica Ltd.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • PhytoHealth Corporation
  • Pieris Pharmaceuticals Inc
  • Sandoz International GmbH
  • SBI Pharmaceuticals Co., Ltd.
  • Therapure Biopharma Inc.
  • Tolero Pharmaceuticals, Inc.

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/2g4lww/chemotherapy

Related Topics: Hematological Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006051/en/

Business Wire
www.businesswire.com

Last updated on: 19/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.